MARKET

MNOV

MNOV

Medicinova
NASDAQ
2.390
-0.080
-3.24%
After Hours: 2.410 +0.02 +0.84% 19:04 12/06 EST
OPEN
2.480
PREV CLOSE
2.470
HIGH
2.540
LOW
2.390
VOLUME
36.63K
TURNOVER
0
52 WEEK HIGH
3.360
52 WEEK LOW
1.960
MARKET CAP
117.22M
P/E (TTM)
-8.9146
1D
5D
1M
3M
1Y
5Y
BRIEF-Medicinova Announces Additional Positive Results About Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress
Reuters · 4h ago
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chie...
GlobeNewswire · 5h ago
MediciNova Announces Results From Secondary Analysis Of Phase 2 Trial Of MN-166 (ibudilast) Published In The American Journal Of Drug And Alcohol Abuse
Benzinga · 1d ago
MNOV: Well Financed to Get Through Tough Market Conditions…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Well-Financed to Advance the Pipeline MediciNova, Inc. (NASDAQ:MNOV) is developing MN-166 and MN-001 for a number of indications with high unmet medical needs. Importantly, ...
Zacks Small Cap Research · 11/18 10:40
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 10/13 14:50
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be condu...
GlobeNewswire · 09/15 23:00
MediciNova to get US patent for MN-166 to treat brain cancer
MediciNova (NASDAQ:MNOV) <a href="https://seekingalpha.com/pr/18...
Seekingalpha · 09/15 09:58
MediciNova Says it Received US Patent Issue Notification for Brain Cancer Drug
MediciNova Says it Received US Patent Issue Notification for Brain Cancer Drug
MT Newswires · 09/15 05:33
More
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.

Webull offers kinds of Medicinova Inc stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.